TOULOUSE, France & ANN ARBOR, Mich.--(BUSINESS WIRE)--April 11, 2006--Cerenis Therapeutics SA (Cerenis), a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular diseases received yesterday in Chicago the "French Life Sciences Award", from AFII, the "Agence Francaise des Investissements Internationaux" at the occasion of the BIO 2006 conference. This prize was given to Cerenis to highlight in particular its innovative products and its entrepreneurial business model.